Refers to a method that comprises administering orally laquinimod or a Salt thereof to a Human patient with Relapsing remitting multiple sclerosis, to reduce or inhibit the progression of fatigue level, to enhance or inhibit the deterioration of Functional status, to enhance or inhibit Deterioration in general health. The laquinimod is administered at a daily dose of 0.3-0.9 mg, in a period of 24 Weeks. Also refers to a method to provide neuroprotection in a Human subject by administering orally laquinimod or a pharmaceutically acceptable Salt thereofSE REFIERE A UN METODO QUE COMPRENDE ADMINISTRAR ORALMENTE LAQUINIMOD O UNA SAL DEL MISMO A UN PACIENTE HUMANO CON ESCLEROSIS MULTIPLE RECURRENTE-REMITENTE, PARA REDUCIR O INHIBIR LA PROGRESION DEL NIVEL DE FATIGA, PARA MEJORAR O INHIBIR EL DETERIORO DEL ESTADO FUNCIONAL, PARA MEJORAR O INHIBIR EL DETERIORO DE LA SALUD GENERAL. EL LAQUINIMOD SE ADMINISTRA EN UNA DOSIS DIARIA DE 0.3-0.9 mg, EN UN PERIODO MAYOR A 24 SEMANAS. SE REFIERE TAMBIEN A UN METODO PARA PROPORCIONAR NEUROPROTECCION A UN SUJETO HUMANO ADMINISTRANDOLE ORALMENTE LAQUINIMOD O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO
